Livzon Pharmaceutical Group Inc.
Livzon Pharmaceutical Group Inc. Fundamental Analysis
Livzon Pharmaceutical Group Inc. (LVZPF) shows moderate financial fundamentals with a PE ratio of 14.69, profit margin of 18.09%, and ROE of 15.39%. The company generates $15.6B in annual revenue with weak year-over-year growth of -4.97%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 55.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze LVZPF's fundamental strength across five key dimensions:
Efficiency Score
WeakLVZPF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentLVZPF trades at attractive valuation levels.
Growth Score
WeakLVZPF faces weak or negative growth trends.
Financial Health Score
ExcellentLVZPF maintains a strong and stable balance sheet.
Profitability Score
ExcellentLVZPF achieves industry-leading margins.
Key Financial Metrics
Is LVZPF Expensive or Cheap?
P/E Ratio
LVZPF trades at 14.69 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, LVZPF's PEG of -5.16 indicates potential undervaluation.
Price to Book
The market values Livzon Pharmaceutical Group Inc. at 2.26 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 15.34 times EBITDA. This signals the market has high growth expectations.
How Well Does LVZPF Make Money?
Net Profit Margin
For every $100 in sales, Livzon Pharmaceutical Group Inc. keeps $18.09 as profit after all expenses.
Operating Margin
Core operations generate 25.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $15.39 in profit for every $100 of shareholder equity.
ROA
Livzon Pharmaceutical Group Inc. generates $8.73 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Livzon Pharmaceutical Group Inc. produces operating cash flow of $3.37B, showing steady but balanced cash generation.
Free Cash Flow
Livzon Pharmaceutical Group Inc. generates strong free cash flow of $3.38B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $2.91 in free cash annually.
FCF Yield
LVZPF converts 6.19% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
14.69
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-5.16
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.26
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.50
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.33
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.25
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.15
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.17
vs 25 benchmark
How LVZPF Stacks Against Its Sector Peers
| Metric | LVZPF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 14.69 | 29.78 | Better (Cheaper) |
| ROE | 15.39% | 792.00% | Weak |
| Net Margin | 18.09% | -23280.00% (disorted) | Strong |
| Debt/Equity | 0.33 | 0.25 | Weak (High Leverage) |
| Current Ratio | 2.25 | 4.60 | Strong Liquidity |
| ROA | 8.73% | -18077.00% (disorted) | Weak |
LVZPF outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Livzon Pharmaceutical Group Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
27.87%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
60.71%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
71.25%
Industry Style: Defensive, Growth, Innovation
High Growth